Merus N.V. Announces Interim Clinical Data From Phase 1/2 eNRGy Trial And Early Access Program Of Zeno
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. has announced interim clinical data from its Phase 1/2 eNRGy trial and early access program of Zeno. The results show a 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients, and a 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients. The company expects to have sufficient clinical data by 1H24 to support potential BLA submissions.
October 23, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus N.V.'s positive interim clinical data from its Phase 1/2 eNRGy trial and early access program of Zeno could potentially boost investor confidence and the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress and potential success of the company's products. This could lead to increased demand for the company's stock, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100